epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg | 48mg

What to Expect with EPKINLY

A guide to treatment

Actor portrayals.

What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with:

- follicular lymphoma (FL) that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab
- follicular lymphoma (FL) that has come back or that did not respond after 2 or more treatments.

It is not known if EPKINLY is safe and effective in children.

SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or lead to death.
- **Neurologic problems** that can be serious, and can be life-threatening and lead to death.
- **Infections and low blood cell counts.**

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9. Please see Medication Guide.

What's inside this guide?

Welcome to EPKINLY 3

About EPKINLY 4

What to do before treatment 5

Important Safety Information 8

What to expect during treatment 10

What to do after treatment 13

Resources 15

Treatment Tracker 18

Appointment Calendar 24

Care Partner tip: Read this guide with your loved one so that you can plan ahead together and get the most out of their treatment with EPKINLY.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Welcome to EPKINLY

Starting a new treatment can prompt a lot of questions. This guide is designed to help you and your Care Partner know what to expect before, during, and after treatment with EPKINLY.

- Use the tabs or the table of contents to easily find what you're looking for
- Use the form on page 38 to keep track of your treatment team
- Remember to download and print two wallet cards (one for you and one for your Care Partner)

Scan the QR code or visit EPKINLY.com/2L-FL for more information

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9. Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

About EPKINLY

EPKINLY is approved with R^2 to treat adults with FL that has returned or that didn't respond after at least 1 treatment. EPKINLY will be given with 2 other medications—lenalidomide and rituximab, which are commonly known as R^2, or "R squared."

EPKINLY is a bispecific antibody treatment that harnesses the power of your own immune system to help fight cancer

It's not chemotherapy or stem cell therapy

You can receive EPKINLY and R^2 at your oncologist's office

SELECT IMPORTANT SAFETY INFORMATION

Important Warnings—EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. Your first full dose of EPKINLY will be given on day 22 of your first cycle of treatment. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9. Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

How often you will receive EPKINLY

Dosing schedule for EPKINLY and R²



Step-up dosing is designed to help you safely adjust to treatment with EPKINLY due to the risk of CRS

*During the first 3 weeks of treatment, you will receive smaller "step-up" doses of EPKINLY than the doses you will receive in week 4 and for the rest of your treatment.

- Before and for 3 days after each dose of EPKINLY in your first 4 weeks of treatment, you will receive other medicines to help reduce your risk of cytokine release syndrome (CRS). Your healthcare provider will decide if you need to receive medicine to help reduce your risk of CRS in later doses of EPKINLY
- Your healthcare provider will decide whether you need to be hospitalized after receiving your first full dose of EPKINLY due to the risk of CRS and neurologic problems
- You may have side effects during treatment. Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts. Your treatment may be temporarily or completely stopped if you develop certain side effects
- If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule

Completing the approximately 11-month course of treatment with EPKINLY and R² may help you live without your FL getting worse

- Your treatment could be delayed or stopped if you have certain side effects

SELECT IMPORTANT SAFETY INFORMATION

Important Warnings—EPKINLY can cause serious side effects, including:

- **Neurologic problems** that can be serious, and can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9. Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

What to do before treatment with EPKINLY

There are some helpful things to know before your visit. Your healthcare provider may also have additional instructions.

Hydration

It is important that you have enough water before you receive your EPKINLY injection.

Start drinking plenty of water the day before your visit. Consider bringing water with you to your visit.

Injection site

Your EPKINLY injection will likely be in the lower abdomen or the thigh.

- Wear loose clothing that is easy to change
- Prepare a cold pack in your freezer in case of any injection site reaction after treatment

Your healthcare provider may receive EPKINLY from a specialty pharmacy, depending on your health insurance. Ask your healthcare provider about how they will receive your treatment. You may get a call from the pharmacy via a 1-800 number to collect any co-pay or co-insurance.

SELECT IMPORTANT SAFETY INFORMATION

People with FL may be hospitalized after receiving their first full dose of EPKINLY on Day 22 of Cycle 1 due to the risk of CRS and neurologic problems.

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. **These may be symptoms of CRS or neurologic problems**. If you have any symptoms that impair consciousness, **do not** drive or use heavy machinery or do other dangerous activities until your symptoms go away.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9. Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Plan for your treatment day

What should I ask?

Before your appointment for your treatment with EPKINLY, see below for suggested questions to ask your healthcare provider to help you plan and prepare.

What do I need to prepare for my visit?

Where should I go for my treatment?

What do I need to know about how I will receive lenalidomide and rituximab?

Will I receive EPKINLY and rituximab during the same visit?

Will I need my Care Partner to drive me to and from my injection visits?

How long will my visit last? Will I be able to go home right after my treatment?

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Important Safety Information

What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with:

- follicular lymphoma (FL) that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab
- follicular lymphoma (FL) that has come back or that did not respond after 2 or more treatments.

It is not known if EPKINLY is safe and effective in children.

IMPORTANT SAFETY INFORMATION
Important Warnings—EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. Your first full dose of EPKINLY will be given on day 22 of your first cycle of treatment. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.
- **Neurologic problems** that can be serious, and can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.

People with FL may be hospitalized after receiving their first full dose of EPKINLY on Day 22 of Cycle 1 due to the risk of CRS and neurologic problems.

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. **These may be symptoms of CRS or neurologic problems**. If you have any symptoms that impair consciousness, **do not** drive or use heavy machinery or do other dangerous activities until your symptoms go away.

EPKINLY can cause other serious side effects, including:

- **Infections** that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, feeling weak or generally unwell, or confusion.
- **Low blood cell counts**, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia and lymphopenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.

Please see additional Important Safety Information on page 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Important Safety Information (continued)

Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. **If you are a female who can become pregnant**, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

The most common side effects of EPKINLY when used alone in FL include CRS, injection site reactions, tiredness, muscle and bone pain, fever, diarrhea, COVID-19, rash, and stomach-area (abdominal) pain. **The most common severe abnormal laboratory test results with EPKINLY when used alone** include decreased white blood cells, decreased red blood cells, and decreased platelets.

The most common side effects of EPKINLY when used together with lenalidomide and rituximab in FL include rash, upper respiratory tract infections, tiredness, injection site reactions, constipation, diarrhea, CRS, pneumonia, COVID-19, and fever. **The most common severe abnormal laboratory test results with EPKINLY when used together with lenalidomide and rituximab** include decreased white blood cells and decreased platelets.

These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on page 8.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

About your injection of EPKINLY

Before your healthcare provider administers your injection of EPKINLY, they will:

- Check your vital signs (temperature, blood pressure, heart rate) and ask you some questions about your general health status
- Check to make sure you are adequately hydrated

Before each dose of EPKINLY in the first 4 weeks, you will receive medications 30 to 120 minutes before your injection to help reduce your risk of CRS, and you will also receive medication for 3 days after each dose. Your healthcare provider will decide if you need to receive medicine to help reduce your risk of CRS with future doses.

During your injection

- EPKINLY will be given as an injection under your skin (subcutaneous injection), usually in the lower part of your stomach area (abdomen) or thigh
- Your healthcare provider will likely switch the injection site at each visit (left to right side or vice versa), especially during your first few weeks of treatment
- You may be asked by your healthcare team to stay longer after the injection so that they can monitor for any reactions
- Your healthcare provider will decide whether you need to be hospitalized after receiving your first full dose of EPKINLY due to the risk of CRS and neurologic problems



Keep track of your injection site locations by using the Treatment Tracker on page 18.

Care Partner tips:

- Use a cold pack to help with any injection site reactions related to treatment with EPKINLY
- Make sure your transportation arrangements can accommodate staying longer after the injection if the healthcare team requests it

SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or lead to death.
- **Neurologic problems** that can be serious, and can be life-threatening and lead to death.
- **Infections and low blood cell counts.**

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9. Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Approved for adults only.

Questions and notes

Following up with your healthcare team

During your first treatment visit for EPKINLY, consider discussing the following with your healthcare team:

What should I do if I miss a dose? _____

Is there anything I need to be aware of while I am receiving EPKINLY with lenalidomide and rituximab? _____

Is there anything I can do to make my overall health better during treatment? _____

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Questions and notes

Write down questions you may have before or during your appointment with your healthcare provider. You can also use this space to take notes.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

What to do between treatments

After you receive a dose of EPKINLY, your healthcare provider will monitor you for any side effects from the treatment, and you should also look out for side effects and any changes in how you're feeling afterward.

EPKINLY can cause serious side effects, including cytokine release syndrome (called CRS), which is common during EPKINLY treatment and can be serious or life-threatening, and neurologic problems that can be life-threatening and lead to death. Other serious side effects include infections that can be serious and lead to death and low blood cell counts, which can be serious or severe.

Watch for symptoms of CRS

CRS symptoms may include:

- Fever of 100.4°F (38°C) or higher
- Dizziness or lightheadedness
- Trouble breathing
- Chills
- Fast heartbeat
- Feeling anxious
- Headache
- Confusion
- Shaking (tremors)
- Problems with balance and movement, such as trouble walking

Tell your healthcare provider or get medical help right away if you develop symptoms of CRS. Your healthcare provider may give you medicines to treat your side effects. Your healthcare provider may temporarily or completely stop your treatment with EPKINLY, depending on your symptoms.

Care Partner tip: Monitor your loved one for signs of fever. Use a thermometer to check frequently for fever of 100.4°F (38°C) or higher in the days following an injection of EPKINLY. Record your loved one's temperature in the Treatment Tracker on pages 18-23 and **alert the healthcare team if their temperature is 100.4°F (38°C) or higher following treatment.**

Remember to carry your **wallet card** with you in the event that a healthcare provider needs quick access to information about your treatment with EPKINLY.

SELECT IMPORTANT SAFETY INFORMATION

The most common side effects of EPKINLY when used alone in FL include CRS, injection site reactions, tiredness, muscle and bone pain, fever, diarrhea, COVID-19, rash, and stomach-area (abdominal) pain. **The most common severe abnormal laboratory test results with EPKINLY when used alone** include decreased white blood cells, decreased red blood cells, and decreased platelets.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9. Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Watch for symptoms of neurologic problems

Neurologic problems may happen days or weeks after you receive EPKINLY. Your healthcare provider may refer you to someone who specializes in neurologic problems.

Symptoms may include but are not limited to:

- Trouble speaking or writing
- Confusion and disorientation
- Drowsiness
- Tiredness or lack of energy
- Muscle weakness
- Shaking (tremors)
- Seizures
- Memory loss

Tell your healthcare provider right away if you develop any symptoms of neurologic problems. You may be given medicines to treat your side effects, and your treatment with EPKINLY may be temporarily or completely stopped.

Care Partner tip: Neurologic problems can affect your loved one's ability to think, remember, and/or use language (verbal or written). These may be subtle or hard to notice at first. If you notice any changes in behavior in your loved one, let the healthcare team know immediately.

Additional important things to know

Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of CRS or neurologic problems.

Watch for symptoms of infection. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection.

Possible side effects you may experience with EPKINLY include but are not limited to: fever of 100.4°F (38°C) or higher; cough; chest pain; tiredness; shortness of breath; painful rash; sore throat; pain during urination; feeling weak or generally unwell; confusion; bruising and bleeding problems.

Tell your healthcare provider right away if you develop any of these symptoms. Your healthcare provider may temporarily or completely stop your treatment with EPKINLY. These are not all the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

MyNavCare Patient Support® is here to support you

MyNavCare® PATIENT SUPPORT

With *MyNavCare*, you can receive personalized support throughout your treatment journey with EPKINLY from a dedicated team that cares

A partner on your treatment journey with EPKINLY

Your healthcare provider is your main source for treatment information. With *MyNavCare*, you gain access to additional resources and medication information.

- Dedicated support throughout your treatment
- Information about treatment access and financial support*
- Insight into independent organizations that may provide additional assistance
- Additional tools and resources that may help along the way

Financial assistance for eligible patients

MyNavCare may be able to help uninsured or underinsured patients receive financial assistance and information. This includes:

- Co-pay assistance program for commercially insured patients*
- Independent patient assistant foundation information†
- Genmab Patient Assistance Program

Ongoing personalized support

Your **Patient Engagement Liaison**‡ is an experienced nurse trained in treatment support as it relates to your specific care. They're dedicated to you, helping to:

- Provide general information about your condition
- Connect you to external organizations that may be able to help
- Offer resources for you and your Care Partners

*Based on eligibility requirements and Terms and Conditions. Federal health care program (FHCP) patients are not eligible for *MyNavCare* copay support.
†Eligibility criteria are determined by each independent third-party foundation. *MyNavCare* does not determine eligibility and cannot guarantee foundations will offer assistance.
‡Patient Engagement Liaisons are provided by *MyNavCare Patient Support*® and do not work under the direction of your doctor or provide medical advice. Patients should speak with their doctor about any treatment-related questions.

Contact a *MyNavCare* Support Specialist by calling 1-866-NAV-CAR1 (1-866-628-2271), Monday–Friday, 8 AM – 8 PM ET. You can also scan the QR code or visit www.MyNavCare.com to learn more.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9. Please see Medication Guide.

epkinly® epcoritamab-bysp SUBCUTANEOUS INJECTION 4mg|48mg

Additional resources

Support for you and your Care Partner

Here are some organizations that can help Patients and Care Partners connect with others, and provide information and resources throughout treatment.

CancerCare
www.cancercare.org | 800-813-HOPE (4673)

American Cancer Society
www.cancer.org | 800-227-2345

Lymphoma Research Foundation
www.lymphoma.org | 800-500-9976

Blood Cancer United
www.bloodcancerunited.org | 800-955-4572

Family Reach
www.familyreach.org | 857-233-2764

Follicular Lymphoma Foundation
www.theflf.org | info@theflf.org

There are many available resources that may be helpful to patients, families, and Care Partners dealing with cancer. The above resources are not controlled, owned, or endorsed by Genmab/AbbVie, and Genmab/AbbVie is not responsible for their content.

If you are a Care Partner

As a Care Partner, you have become an integral part of your loved one's healthcare team.

Some responsibilities you may take on during your loved one's treatment:

- **Decision-making:** Researching clinical trials and treatment options, helping to consider treatment choices, and being an advocate for your loved one
- **Emotional:** Encouraging your loved one to share their feelings and helping them feel supported
- **Treatment support:** Helping watch for potential side effects, attending appointments, and ensuring they have what they need throughout their treatments
- **Logistical:** Scheduling and driving them to appointments, running errands, and assisting with daily needs

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Track important information here

Record your experience with EPKINLY and R^2 and share with your healthcare team so they get a full picture of how you're doing on treatment.

- Keep track of the appointment date for each EPKINLY dose
- Mark the location of the EPKINLY injection site
- Record your temperature as instructed by your healthcare team
- Write down how you're feeling after treatment and any other information you want to share

EPKINLY injection:



Location

Dose: _____

Date: _____

Time: _____

Rituximab infusion:

Date: _____

Time: _____

My temperature:

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

How I'm feeling: _____

_____

Questions/notes for my healthcare team: _____

_____

Here are some tips to help you remember to take your lenalidomide pill:

- Set an alarm or medication reminder on your phone
- Create a routine by taking your pill during something you do at the same time every day, like brushing your teeth or mealtimes
- Use the calendar on the following pages to track your medication

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9. Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Treatment Tracker

EPKINLY injection:



Location

Dose: _____

Date: _____

Time: _____

Rituximab infusion:

Date: _____

Time: _____

My temperature:

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

How I'm feeling: _____

_____

Questions/notes for my healthcare team: _____

_____

EPKINLY injection:



Location

Dose: _____

Date: _____

Time: _____

Rituximab infusion:

Date: _____

Time: _____

My temperature:

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

How I'm feeling: _____

_____

Questions/notes for my healthcare team: _____

_____

_____

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9. Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Treatment Tracker

EPKINLY injection:



Location

Dose: _____

Date: _____

Time: _____

Rituximab infusion:

Date: _____

Time: _____

My temperature:

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

How I'm feeling: _____

_____

Questions/notes for my healthcare team: _____

_____

EPKINLY injection:



Location

Dose: _____

Date: _____

Time: _____

Rituximab infusion:

Date: _____

Time: _____

My temperature:

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

How I'm feeling: _____

_____

Questions/notes for my healthcare team: _____

_____

_____

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9. Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Treatment Tracker

EPKINLY injection:



Location

Dose: _____

Date: _____

Time: _____

Rituximab infusion:

Date: _____

Time: _____

My temperature:

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

How I'm feeling: _____

_____

Questions/notes for my healthcare team: _____

_____

EPKINLY injection:



Location

Dose: _____

Date: _____

Time: _____

Rituximab infusion:

Date: _____

Time: _____

My temperature:

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

How I'm feeling: _____

_____

Questions/notes for my healthcare team: _____

_____

_____

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9. Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Treatment Tracker

EPKINLY injection:



Location

Dose: _____

Date: _____

Time: _____

Rituximab infusion:

Date: _____

Time: _____

My temperature:

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

How I'm feeling: _____

_____

Questions/notes for my healthcare team: _____

_____

EPKINLY injection:



Location

Dose: _____

Date: _____

Time: _____

Rituximab infusion:

Date: _____

Time: _____

My temperature:

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

How I'm feeling: _____

_____

Questions/notes for my healthcare team: _____

_____

_____

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9. Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Treatment Tracker

EPKINLY injection:



Location

Dose: _____

Date: _____

Time: _____

Rituximab infusion:

Date: _____

Time: _____

My temperature:

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

How I'm feeling: _____

_____

Questions/notes for my healthcare team: _____

_____

EPKINLY injection:



Location

Dose: _____

Date: _____

Time: _____

Rituximab infusion:

Date: _____

Time: _____

My temperature:

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

Temperature: _____ Date: _____ Time: _____

How I'm feeling: _____

_____

Questions/notes for my healthcare team: _____

_____

_____

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9. Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Calendar

Use this calendar to keep track of your healthcare appointments, including treatments (injections, infusions, and pills) and tests. Make notes here prior to the appointment if you have questions for your healthcare provider.

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Calendar

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Calendar

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Calendar

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Calendar

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Calendar

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Calendar

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Calendar

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Calendar

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Calendar

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Calendar

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Calendar

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Calendar

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Questions and notes

Write down questions you may have before or during your appointment with your healthcare provider. You can also use this space to take notes.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Important contact information

Write down contact information for members of your healthcare team and other emergency contacts for quick and easy access.

My Doctor

Name: _____

Phone number: _____

Office address: _____

My Nurses

Name: _____

Phone number: _____

Office address: _____

Name: _____

Phone number: _____

Office address: _____

My Pharmacy

Name: _____

Phone number: _____

Pharmacy address: _____

My Emergency Contact

Name: _____

Phone number: _____

If you notice any side effects or unusual symptoms, reach out to your healthcare team right away.

It's a good idea to keep this info in your mobile phone as well. You can even just take a picture of this page.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9. Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Scan the QR code or visit EPKINLY.com/2L-FL for more information

Actor portrayals.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 8 and 9. Please see Medication Guide.

Genmab | abbvie

Distributed and marketed by Genmab US Inc. 777 Scudders Mill Road, Plainsboro, NJ 08536. Distributed and marketed by AbbVie Inc. 1 North Waukegan Road, North Chicago, IL 60064.
EPKINLY and *MyNavCare Patient Support* are trademarks of Genmab A/S.
All other trademarks are the property of their respective owners.
©2026 Genmab A/S and AbbVie. All rights reserved.
05/2026 COM-US-EPK-0002661

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg